芦可替尼乳膏治疗特应性皮炎的效果怎么样

Ruxolitinib cream has a significant effect in the treatment of atopic dermatitis. It can effectively control and relieve the inflammatory reaction, reduce itching and erythema, and improve the hydration capacity of the skin, thereby significantly reducing the patient's discomfort. Studies have shown that ruxolitinib cream is highly effective in improving disease symptoms in multiple mouse dermatitis models by downregulating T helper (Th)2-driven inflammation, thereby reducing skin thickening and itching.

In 2 double-blind Phase 3 atopic dermatitis studies (NCT03745638/NCT03745651), ruxolitinib cream was shown to be safe and effective over 8 weeks.

Methods: Patients were initially randomized to ruxolitinib 0.75%/1.5% cream twice daily and maintained on their regimen (treat as needed) during 44 weeks of LTS. At Week 8, patients on vehicle were again randomized (1:1) to ruxolitinib cream strength. Safety and disease control were assessed (investigator's global assessment score 0/1 and affected body surface area).

Results: Over 52 weeks, 67.4%/62.6%/53.5%/57.6% of patients in the 0.75%/1.5% ruxolitinib cream/vehicle to 0.75% ruxolitinib cream/vehicle to 1.5% ruxolitinib cream group reported adverse events (n=426/446/101/99). The most common adverse events were upper respiratory tract infection (10.3%/11.4%/5.9%/7.1%) and nasopharyngitis (8.9%/9.9%/7.9%/14.1%). Most adverse events were considered unrelated to treatment. Application site reactions were rare (3.8%/1.8%/1.0%/1.0%).

Disease control was achieved throughout LTS; 74.1% to 77.8% of patients had investigator global assessment at Week 52, and the mean affected body surface area was low (1.4% to 1.8%).

Conclusions: Ruxolitinib cream demonstrated effective disease control and tolerability during 44 weeks of on-demand treatment.

Common side effects of ruxolitinib cream include pain or swelling in the nose or throat (nasopharyngitis), diarrhea, increased eosinophil (a type of white blood cell) count, urticaria, bronchitis, ear infection, folliculitis, tonsillitis, runny nose, etc. Patients' physical constitution and condition are different, and side effects are also different. Some patients may develop serious infections, malignant tumors, cardiovascular events, and thrombosis. It is recommended that patients follow the doctor's advice and receive symptomatic treatment.

Recommended related articles:

References

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, Kuligowski ME, Kallender H, Sun K, Ren H, Simpson EL. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. J Am Acad Dermatol. 2023 May;88(5):1008-1016. doi: 10.1016/j.jaad.2022.09.060. Epub 2022 Nov 26. PMID: 36574595.